Format

Send to:

Choose Destination
See comment in PubMed Commons below
Med Monatsschr Pharm. 2013 Jan;36(1):14-24.

[nab-Paclitaxel. Clinical value of an innovative taxane-containing formulation].

[Article in German]

Author information

  • 1Apotheke des Universitätsklinikums Tübingen, Röntgenweg 9, 72076 Tübingen. Hans-Peter.Lipp@med.uni-tuebingen.de

Abstract

Nanoparticle-albumin bound paclitaxel (nab-paclitaxel) represents an innovative taxane-containing formulation lacking any critical solvents with minimal risks for any hypersensitivity reactions as well as perspectives for dose escalation as a consequence. Preclinical data indicated an increase of drug accumulation in tumor tissues via nab-paclitaxel administration which appears to be related to direct interaction with albumin-binding proteins including stromal SPARC. Phase III study results revealed clinically relevant advantages regarding efficacy and tolerability associated with nab-paclitaxel compared to conventional docetaxel and paclitaxel in patients with metastatic breast cancer. Further experience may encourage its use in other tumor entities including NSCLC, ovarian and pancreatic carcinoma as well as melanoma. As a consequence, the development of algorithms is ongoing in order to be able to select patients in more detail who will particularly benefit from nab-paclitaxel treatment.

PMID:
23379109
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk